This phase I trial is trying to understand if a new oral targeted therapy is safe and effective as a monotherapy or in combination with another cancer treatment in patients with advanced cancer.
This trial is treating multiple types of cancer including breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer and ovarian cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Eli Lilly and Company, in collaboration with Merck Sharpe & Dohme Corp.
This trial contains several cohorts, across which eligible patients will be randomised to receive oral LY3475070 alone or in combination with intravenous pembrolizumab.
Recruiting Hospitals Read More